体内外研究表明实体性肿瘤的生长是依赖血管的，其直径一旦超过2 mm，若没有新生的血管供血则肿瘤的生长就会停止。胶质瘤是人体内血管化程度最高恶性的肿瘤之一。胶质瘤的血管发生与其他实体性肿瘤血管发生一样，由血管形成及血管新生两种方式构成：前者由内皮祖细胞或者血管母细胞形成新的血管；而后者是由组织中既存的成熟血管的内皮细胞发生增殖和游走形成小血管。血管新生是肿瘤血管生成的主要形式，胶质瘤血管新生的机制研究以及抑制其血管生成是胶质瘤治疗的一个新途径，成为近年来的研究热点，本文就胶质瘤血管新生及其调控机制作一综述。

Studies in vitro show that the growth of solid tumor is vessel dependent. Solid tumor usually stops growing when its diameter is over 2 mm due to lack of new vessel to supply blood. Glioma is one of the most malignant tumor in vascularization. As a solid tumor, the vascularization in glioma also includes vasculogenesis and angiogenesis. Vasculogenesis is defined as the differentiation of precursor cells (angioblasts) into endothelial cells and the de novo formation of a primitive vascular network, whereas angiogenesis is defined as the growth of new capillaries from pre-existing blood vessels. Angiogenesis, which plays a significant role in the development of tumor, has become a new target for the prognostic evaluation and therapy of glioma. Recently, the research in exploring the mechanism of angiogenesis has attracted great attention.

国家自然科学基金

［1］Tuettenberg J, Friedel C, Vajkoczy P. Angiogenesis in malignant glioma-a target for antitumor therapy?［J］. Crit Rev Oncol Hematol, 2006, 59(3):181-193.
［2］Jouanneau E. Angiogenesis and gliomas: current issues and development of surrogate markers［J］. Neurosurgery, 2008, 62(1):31-50.
［3］Khosravi Shahi P, Fernández Pineda I. Tumoral angiogenesis: review of the literature［J］. Cancer Invest, 2008, 26(1):104-108.
［4］Breier G, Licht AH, Nicolaus A, et al. HIF in vascular development and tumour angiogenesis［J］ . Novartis Found Symp, 2007, 283:126-33; discussion 133-138,238-241.
［5］Ratcliffe PJ, Pugh CW, Maxwell PH. Targeting tumors through the HIF system［J］ . Nat Med, 20006,6(12):1315-1316.
［6］Veeravagu A, Hsu AR, Cai W, et al. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy［J］. Recent Pat Anticancer Drug Discov, 2007, 2(1):59-71.
［7］Ergun N, Kilic W, Fiedler S, et al. Vascularendothelial growth factor and its receptors in normal human testicular tissue［J］. Mol Cell Endocrinol, 1997, 131(1):9-20.
［8］Bulnes S, Lafuente JV. VEGF immunopositivity related to malignancy degree, proliferative activity and angiogenesis in ENU-induced gliomas［J］. J Mol Neurosci, 2007, 33(2):163-172.
［9］Neufeld G，Kessler O，Herzog Y.The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF［J］.Adv Exp Med Biol，2002，515：81-90.(Review)
［10］Brekken RA，Overholser JP，Stastny VA，et al. Selective inhibition of vascula endothelial growth factor(VEGF)receptor 2(KDR／FIk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice［J］.Cancer Res，2000，60(18)：5117-5124.
［11］Nomi M, Miyake H, Sugita Y, et al. Role of growth factors and endothelial cells in therapeutic angiogenesis and tissue engineering［J］. Curr Stem Cell Res Ther, 2006, 1(3):333-343.
［12］Joseph-Silverstein J, Rifkin DB. Endothelial cell growth factors and the vessel wall［J］. Semin Thromb Hemost, 1987, 13(4):504-513.
［13］Shepherd FA. Angiogenesis inhibitors in the treatment of lung cancer［J］. Lung Cancer, 2001, 34 (Suppl 3):S81-89.
［14］Wang DL, Wang YF, Shi GS, et al. Correlation of hTERT expression to maspin and bFGF expression and their significance in glioma［J］. Ai Zheng, 2007, 26(6):601-606.
［15］Ganter MT, Cohen MJ, Brohi K, et al. Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma?［J］. Ann Surg, 2008, 247(2):320-326.
［16］Lee OH, Fueyo J, Xu J, et al. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth［J］. Neoplasia, 2006, 8(5):419-248.
［17］Hu B, Jarzynka MJ, Guo P, et al. Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway［J］. Cancer Res, 2006, 66(2):775-783.
［18］Fitch MJ, Campagnolo L, Kuhnert F, et al. Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells［J］. Dev Dyn, 2004, 230(2):316-324.
［19］Campagnolo L, Leahy A, Chitnis S, et al. EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury［J］. Am J Pathol, 2005, 167(1):275-284.
［20］De Mazière A, Parker L, Van Dijk S, et al. Egfl7 knockdown causes defects in the extension and junctional arrangements of endothelial cells during zebrafish vasculogenesis［J］. Dev Dyn, 2008, 237(3):580-591.
［21］Schmidt M, Paes K, De Mazière A, et al. EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution［J］. Development, 2007, 134(16):2913-2923.
［22］Lynch PM, Schmid-Schnbein GW. Parker LH, et al. The endothelial-cell-derived secreted factor Egf17 regulates vascular tube formation［J］. Nature, 2004, 428(6984):754-758.
［23］Schmidt M, De Mazière A, Smyczek T, et al. The role of Egfl7 in vascular morphogenesis［J］. Novartis Found Symp, 2007, 283:18-28, discussion 28-36, 238-241.
［24］Xu D, Perez RE, Ekekezie II, et al. Epidermal growth factor-like domain 7 protects endothelial cells from hyperoxia-induced cell death［J］. Am J Physiol Lung Cell Mol Physiol, 2008, 294(1):L17-23.
［25］Prince LS. Hyperoxia and EGFL7: saving cells from too much of a good thing［J］. Am J Physiol Lung Cell Mol Physiol, 2008, 294(1):L15-16.
［26］Gustavsson M, Mallard C, Vannucci SJ, et al. Vascular response to hypoxic preconditioning in the immature brain［J］. J Cereb Blood Flow Metab, 2007, 27(5):928-938.
［27］Jiang WD, Zeng JP, Qin AQ, et al. siRNA inhibits efgl7 expression in human endothelial cell line HUVEC［J］. Zhonghua Xin Xue Guan Bing Za Zhi, 2006, 34(7):643-646.
［28］Feldkamp MM, Lau N, Rak J, et al. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras［J］. Int J Cancer, 1999, 81(1):118-124.
［29］Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity［J］. Cancer Res, 2004, 64(14):4931-4941.
［30］O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth［J］. Cell, 1997, 88(2):277-285.
［31］Cui R, Takahashi K, Takahashi F, et al. Endostatin gene transfer in murine lung carcinoma cells induces vascular endothelial growth factor secretion resulting in up-regulation of in vivo tumorigenecity［J］. Cancer Lett, 2006, 232(2):262-271.
［32］Jia LJ, Xu HM, Ma DY, et al. Enhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma model［J］. Cancer Biol Ther, 2005, 4(8):840-845.
［33］Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance［J］. Nature, 1997, 390(6658):404-407.
［34］Wen XY, Bai Y, Stewart AK. Adenovirus-mediated human endostatin gene delivery demonstrates strain-specific antitumor activity and acute dose-dependent toxicity in mice［J］. Hum Gene Ther, 2001, 12(4):347-358.
［35］Miller WJ, Kayton ML, Patton A, et al. A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assay［J］. J Transl Med, 2004, 2(1):4.
［36］Read TA,Farhadi M,Bjerkvig R, et al. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate encapsulated cells［J］. Cancer ES, 2001, 61(18):6830-6837.
［37］Shiratsuchi T, Nishimori H, Ichise H, et al. Cloning and characterization of BAI2 and BAI3, novel genes homologous to brain-specific angiogenesis inhibitor 1 (BAI1)［J］. Cytogenet Cell Genet, 1997, 79(1-2):103-108.
［38］Kaur B, Brat DJ, Calkins CC, et al. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression［J］. Am J Pathol, 2003, 162(1):19-27.
［39］Colorado PC, Torre A, Kamphaus G, et al. Anti-angiogenic cues from vascular basement membrane collagen［J］. Cancer Res, 2000, 60(9):2520-2526.
［40］Mundel TM, Kalluri R. Type IV collagen-derived angiogenesis inhibitors［J］. Microvasc Res, 2007, 74(2-3):85-89.
［41］Winkler F, Kienast Y, Fuhrmann M, et al. Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis［J］. Glia, 2009,57(12):1306-1315.
［42］Zagzag D, Lukyanov Y, Lan L, et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion［J］. Lab Invest, 2006, 86(12):1221-1232.
［43］Zhen HN, Li LW, Zhang W, et al. Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cell［J］. Int J Oncol, 2007, 31(5):1111-1117.
［44］Kaur B, Cork SM, Sandberg EM, et al. Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism［J］. Cancer Res, 2009, 69(3), 1212-1220.
［45］Zhang Y, Zhang N, Dai B, et al. FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells［J］. Cancer Res, 2008, 68(21):8733-8742.